Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

Fri, 10th May 2019 09:36

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed in the period.

For the six months to the end of March, the trust's net asset value negative return was 3.0%, compared to the 2.3% negative return by the MSCI ACWI/Healthcare Index in sterling terms, with dividends reinvested.

Net asset value per share as at March 31 was 233.53 pence, up from 183.00p the same date the year before, but down from 241.91p at the end of September.

Polar Capital's share price at the end of March was 216.00p, reflecting a discount to net asset value of 7.5%, widened from 6.1% the year before.

Shares in Polar Capital Global Healthcare were down 1.0% on the day Friday at 203.50 pence, having fallen 5.8% since the period-end.

The trust said that the overall healthcare market "modestly underperformed", with major sell-offs in October and December due to trade friction, slowing global growth, as well as political uncertainties.

Detractors within the trust's portfolio includes Diurnal Group PLC, which reported that its congenital adrenal hyperplasia treatment product Chronocort failed to meet its primary objective in its phase three trial.

Another detractor was Consort Medical PLC, due to delays in some of its customer projects.

However, stocks that performed well were Merck & Co Inc, with strong momentum in its immuno-oncology and vaccines businesses, and Renalytix AI PLC, due to progress in the development of its AI-enabled product for treating kidney diseases.

"While backward looking, the temperamental, almost nervous nature of the market further underpins our view that large-cap healthcare companies should be a relatively attractive place to invest in the near to medium term," Polar Capital Global Healthcare said.

"With technology at the fore, we continue to believe we can find companies within our investment universe that are capable of delivering mid to high single-digit, organic, top-line growth, operating leverage as well as high single to low double-digit total shareholder returns," the trust added.

More News
21 Apr 2021 17:59

TRADING UPDATES: Diurnal taps GBP20 million; Victoria buys new assets

TRADING UPDATES: Diurnal taps GBP20 million; Victoria buys new assets

Read more
15 Apr 2021 19:37

TRADING UPDATES: HSBC announces redemption of US dollar securities

TRADING UPDATES: HSBC announces redemption of US dollar securities

Read more
26 Mar 2021 14:36

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

TRADING UPDATES: Renew to buy J Browne; Idox in good start to year

Read more
23 Feb 2021 16:23

Alkindi sales drive revenue higher for Diurnal

(Sharecast News) - Speciality pharmaceuticals company Diurnal reported 6% growth in first-half total revenue in its interim results on Tuesday, to £1.21m.

Read more
23 Feb 2021 12:28

UPDATE: Diurnal Loss Widens In First Half; Signs Chronocort Deal

UPDATE: Diurnal Loss Widens In First Half; Signs Chronocort Deal

Read more
23 Feb 2021 12:15

Diurnal Reports Widened Loss In First Half Despite Revenue Growth

Diurnal Reports Widened Loss In First Half Despite Revenue Growth

Read more
16 Feb 2021 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
27 Jan 2021 09:22

Diurnal Inks Licence Agreement For Alkindi With Citrine Medicine

Diurnal Inks Licence Agreement For Alkindi With Citrine Medicine

Read more
14 Jan 2021 19:15

UK TRADING UPDATE SUMMARY: DWF Sets Up New Global Operating Structure

UK TRADING UPDATE SUMMARY: DWF Sets Up New Global Operating Structure

Read more
14 Jan 2021 15:18

IN BRIEF: Diurnal Pleased With Alkindi Sales In First Half

IN BRIEF: Diurnal Pleased With Alkindi Sales In First Half

Read more
13 Jan 2021 14:36

IN BRIEF: Diurnal Inks Turkey Distribution Deal For Alkindi, Chronocort

IN BRIEF: Diurnal Inks Turkey Distribution Deal For Alkindi, Chronocort

Read more
12 Jan 2021 19:12

IN BRIEF: Diurnal Submits Application To UK Regulators For Chronocort

IN BRIEF: Diurnal Submits Application To UK Regulators For Chronocort

Read more
11 Jan 2021 13:22

IN BRIEF: Diurnal Inks European Patent For Chronocort

IN BRIEF: Diurnal Inks European Patent For Chronocort

Read more
20 Nov 2020 18:03

IN BRIEF: Diurnal Secures Grant Of European Patent For Alkindi

IN BRIEF: Diurnal Secures Grant Of European Patent For Alkindi

Read more
20 Nov 2020 12:04

Diurnal gets European patent for 'Alkindi'

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.